Loading patent…
OwnerMichael Oettel, Ludwig Wild +4inventors
InventorsMichael Oettel, Ludwig Wild, Peter Licht, Joachim Neuwinger, Wolfgang Hummel, Ralph Dittrich
Estimating the term…
The pharmaceutical preparations for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) contain an effective amount of a chemically modified derivative of 17α-estradiol, a chemically modified derivative of 17β-estradiol and/or a chemical modified derivative of estriol. Pharmaceutical preparations containing estra 1,3,5(10)-triene-3,17β-diol-17-valerate as the effective ingredient are particularly preferred.
A method of reducing side effects resulting from treatment of a human female with analogs or antagonists of gonadotropin-releasing hormone, said method comprising, during, after or during and after said treatment with said analogs or said antagonists of said gonadotropin-releasing hormone, administering to said human female an effective amount of estra 1,3,5(10)-triene-3,17β-diol-17-valerate, said effective amount being effective to reduce said side effects resulting from said treatment of said human female with said analogs or said antagonists.
A method of reducing side effects resulting from treatment of a human male with analogs or antagonists of gonadotropin-releasing hormone, said method comprising, during, after or during and after said treatment with said analogs or said antagonists of said gonadotropin-releasing hormone, administering to said human male an effective amount of estra 1,3,5(10)-triene-3,17β-diol-17-valerate, said effective amount being effective to reduce said side effects resulting from said treatment of said human male with said analogs or said antagonists.
A pharmaceutical preparation for reducing side effects resulting from treatment with analogs or antagonists of gonadotropin-releasing hormone, said pharmaceutical preparation comprising an effective amount of said estra 1,3,5(10)-triene-3,17β-diol-17-valerate, said effective amount being effective to reduce said side effects resulting from said treatment with said analogs or said antagonists, in a solid or liquid vehicle with at least one diluent or adjuvant.
Dependencies are inferred from the claim text.